Findings from the MONALEESA-7 trial (NCT02278120) were presented during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in the late-breaking presentation, “Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.”
They were published simultaneously in The New England Journal of Medicine.
Kisqali is a targeted therapy developed by Novartis. It blocks the activity of cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. CDKs are proteins that help control the process of cell division; in the case of cancer, these proteins can spur tumor growth.
“Kisqali has characte